sizcache="" sizset="47">
Why do many people with breast cancer need to have chemotherapy? The reason is that despite the perfect efforts of the healthcare team to remove all traces of the tumor, breast cancer can nonetheless recur. Even early stage breast cancer can return months to years just after the original diagnosis and treatment.
It can come back as a neighborhood recurrence (in the treated breast) or as a distant recurrence, also recognized as metastatic illness, elsewhere in the body, such as the bones, lungs, liver, or other organs. Due to this concern, numerous oncologists prefer to err on the side of more than treating their patients with chemotherapy, lest the individual be under treated and sustain a recurrence.
There are specific standard prognostic variables that influence a doctor's decision to prescribe chemotherapy. These incorporate the age and general health of the individual as properly as the size of the breast tumor, the status of the lymph nodes (positive versus negative), and the presence or absence of estrogen receptors on the tumor. Tiny tumors with positive estrogen receptors and negative lymph nodes tend to be less aggressive.
Examining the statistics, perhaps up to 15 out of 100 (15%) of patients with less aggressive tumors will create a recurrence. Until recently, to save the lives of those 15 men and women, medical oncologists needed to treat all 100 patients, as they did not have the tools to identify which of the 100 patients were the 15 who were bound to recur. This meant that 85 out of the 100 folks were over treated with chemotherapy.
The question then arises: which of these people today can be comfortably spared chemotherapy, as nicely as its side effects? Also, of those many people who undergo a lumpectomy and need breast radiation therapy, who can stay away from the delay in radiation therapy imposed by the have to have to complete chemotherapy 1st?
To answer this question, a new diagnostic test that measures the likelihood of breast cancer recurrence has been created. It also assesses the benefit from chemotherapy. The test is known as Oncotype DX(TM) and it is appropriate for breast cancer patients who are:
· Newly diagnosed
· Stage I or II (early stage)
· Lymph node-negative
· Estrogen receptor positive and
· Those who will be treated with tamoxifen, an oral medication that interferes with the dangerous effect of estrogen on breast cancer cells.
All breast cancer tumors are genetically distinctive. Many of the genetic differences among individual tumors influence the likelihood that the cancer will recur. These differences are associated in portion with the level of expression of a certain group of cancer-associated genes. Oncotype DX(TM) is the to begin with cancer test that utilizes the unique genetic expression the patient's tumor to quantify the likelihood that breast cancer will recur.
Oncotype DX(TM) examines the expression of the aforementioned distinct group of genes and makes use of a mathematical equation to translate it into a Recurrence Score(TM). The Recurrence Score(TM) accurately quantifies the likelihood of distant recurrence, and its predictive energy exceeds that of the previously described normal prognosticators.
The results are scored in the lowest, intermediate, and highest danger range. Oncotype DX(TM) outcomes boost confidence that the treatment strategy is tailored to the individual patient by helping physicians figure out who will benefit the most from chemotherapy.
Clearly, the highest risk consumers will be advised to accept chemotherapy. The lowest danger group can forego chemotherapy. The greatest controversy lies with the intermediate danger group.
Hence, a randomized clinical trial is at the moment examining what is the most beneficial strategy for the intermediate risk population. The study will accrue practically 10,000 men and women and participants will be followed for at least 5 years.
The good news is that with the advent of this new diagnostic test, men and women can be selected more carefully for chemotherapy. These folks can then have the peace of thoughts of understanding that they are not leaving any stone unturned and are undertaking the ideal they can to reduce the likelihood that their cancer will recur. On the flip side, low risk persons can be advised to waive chemotherapy and have a greater comfort level that their disease will not be most likely to recur as a consequence.
Dr. Kornmehl is a board certified radiation oncologist at St. Mary's Passaic Hospital, Passaic, NJ, and author of the critically acclaimed consumer wellness book, "The Top News About Radiation Therapy" (M. Evans, 2004). Her Webpage is
No comments:
Post a Comment